Business
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant settingTrial is anticipated to begin enrolling in H1’2026 BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the planned initiation of an investigator-initiated Phase 1 neoadjuvant study of
About this update from Elicio Therapeutics, Inc.
[{"type":"image","alt":"Elicio Therapeutics Inc.","displaySize":"","headline":null,"caption":"Elicio Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dHRdNHTDYzkn3cTM5JZhnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant setting","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"Trial is anticipated to begin enrolling in H1’2026","length":50,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":175,"olType":false},{"type":"text","content":"BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the planned initiation of an investigator-initiated Phase 1 neoadjuvant study of ELI-002 7P in combination with chemotherapy and an anti-PD1 checkpoint inhibitor in borderline and resectable pancreatic ductal adenocarcinoma (“PDAC”). The multi-center investigator-initiated trial (“IIT”) will be led by principal investigator, Kevin Soares, M.D., from Memorial Sloan Kettering Cancer Center (“MSK”), and is being funded by the Lustgarten Foundation.","length":697,"tagName":"p"},{"type":"text","content":"The IIT will evaluate mFOLFIRINOX in combination with ELI-002 7P, with or without the anti–PD-1 antibody. The study is designed to enroll 20 patients across two cohorts (10 per arm). The trial is expected to commence in H1’2026.","length":228,"tagName":"p"},{"type":"text","content":"“We are entering an exciting era in pancreatic cancer treatment, where combining standard neoadjuvant chemotherapy with innovative immunotherapies has the potential to offer real hope. PDAC, unfortunately, has remained refractory to single-agent immune checkpoint inhibitors due to low infiltration of T-cells to the tumor site and low PD-1/PD-L1 expression. Targeting the immunosuppressive PDAC tu...